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Abstract: Breast Cancer (BC) is the leading cause of death due to cancer in women. Ensuring
equitable, quality-assured and effective care has increased the complexity of BC management. This
systematic review reports on the state-of-the art of available literature investigating the enactment
of personalized treatment and patient-centered care models in BC clinical practice, building a
framework for the delivery of personalized BC care within a Patient-Centered model. Databases
were searched for articles (from the inception to December 2020) reporting on Patient-Centered
or Personalized Medicine BC management models, assessing success factors or limits. Out of
1885 records, 25 studies were included in our analysis. The main success factors include clearly
defined roles and responsibilities within a multi-professional collaboration, appropriate training
programs and adequate communication strategies and adopting a universal genomic language to
improve patients’ involvement in the decision-making process. Among detected barriers, delays
in the use of genetic testing were linked to the lack of public reimbursement schemes and of clear
indications in timing and appropriateness. Overall, both care approaches are complementary and
necessary to effectively improve BC patient management. Our framework attempts to bridge the gap
in assigning a central role played by shared decision-making, still scarcely investigated in literature.
Keywords: personalized medicine; Patient Centered Care; breast cancer management; organizational
model; systematic review
1. Introduction
Among today’s major public health concerns, female Breast Cancer (BC) is responsible
for an estimated 2.3 million new cases every year, surpassing lung cancer as the most
commonly diagnosed cancer (11.7% of all cases) and leading cause of death due to cancer
in women [1]. Efforts towards guaranteeing standardized, quality-assured and effective
care have led to an increasing complexity and specialization of BC management, inevitably
backed by an integration of multi-specialist inputs provided collaboratively through the
efforts of several healthcare practitioners. Multidisciplinary care in BC, represented by
the Breast Unit model, has become the gold-standard of patient-centered BC care and has
been included among the determinants for accreditation and funding of facilities, given its
capacity to improve patients’ quality of life and survival rates [2–4].
Complementarily, advances in diagnosis and treatment have equipped clinical practice
with ensembles of newly developed targeted therapies [5] and personalized medicine
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techniques that are gradually improving outcomes and survival, as recent research is
equipping specialists with a broader understanding of the biology and heterogeneity of BC,
of mechanisms behind tumour resistance and with the possibility of predicting patients’
responses to therapies, especially when dedicated clinical governance tools (i.e., molecular
tumour boards) are instituted within the care pathway.
Despite such documented progress, literature seems to highlight that the application
of such innovations into routine clinical practice is proceeding at a slower pace compared
to the generation of such findings [6], stressing the need to concentrate efforts on their
implementation into real-life settings.
The aim of this systematic review is two-fold. First, to report on the state-of-the art
of available literature investigating the enactment of personalized treatment and patient-
centered care models in BC clinical practice. Second, to propose a comprehensive care
management framework for the delivery of personalized care to patients with BC, within a
patient-centered care model.
2. Materials and Methods
This systematic review was conducted and reported according to the Preferred Re-
porting Items for Systematic Reviews and Meta-Analyses statement [7].
2.1. Search Strategy
The electronic databases of Web of Science, PubMed, Scopus were searched to re-
trieve potential eligible articles, published in English from the inception to December
2020. A Boolean search string was created using the elements of the PICO model (P,
population/patient; I, intervention/indicator; C, comparator/control; and O, outcome).
Furthermore, the search on Scopus was restricted to only humans, English language,
“medicine” subject area, document types—articles, reviews, editorials, letters—and pub-
lication stage—final articles. Keywords such as “breast cancer management”; “breast
units”; “personalized medicine”; “patient centeredness”; “patient-centered care”; “multi-
disciplinary team”; “tumor board”; “molecular tumor board”; “success factors”; “limits”;
“cost effectiveness” were used.
2.2. Inclusion/Exclusion Criteria
Articles reporting breast cancer management in terms of patient-centered care and per-
sonalized medicine approaches were considered eligible. Studies mainly discussing breast
cancer clinical therapeutics, clinical epidemiological data or surgical data were excluded.
For the purpose of our study, we used the European Commission definition, according
to which “Personalized medicine” is “A medical model using characterization of indi-
viduals’ phenotypes and genotypes (e.g., molecular profiling, medical imaging, lifestyle
data) for tailoring the right therapeutic strategy for the right person at the right time,
and/or to determine the predisposition to disease and/or to deliver timely and targeted
prevention” [8].
Similarly, we used the IOM (Institute of Medicine) definition of Patient-Centered care
as “care that is respectful of and responsive to individual patient preferences, needs, and
values” and that ensures “that patient values guide all clinical decisions” [9].
Relying on Rotter’s 2010 Cochrane Review, the key dimensions identified for Pa-
tient Centered Care were communication [10], audit/feedback [11], informative sys-
tems [12], evidence-based application [13], multidisciplinary approach [14] and education
sessions [11]. With regards to Personalized Medicine, on the other hand, the European
Council’s document of 2015 identifies the molecular board [15], evidence-based genetic
testing [16] and shared-clinical decision-making [17]. As such, eligible studies were those
fulfilling t the definitions of patient-centered care and/or personalized medicine in terms
of inclusion of the aforementioned dimensions.
In parallel, when available, relative key success factors and barriers to implementation
of such dimensions were reported.
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2.3. Study Selection
After removing duplicate records, four researchers (C.C., A.M., R.P., R.P.) indepen-
dently screened by title and abstract to outline records according to the inclusion criteria
aforementioned. Then, the four researchers performed a full text screening of each article
to determine eligibility. Disagreements were resolved through discussion with a fifth
researcher (A.G.d.B.).
The reference lists of the included studies were hand-searched to locate additional
studies via the snowball search method. The study selection was performed from December
2020 to February 2021.
2.4. Data Extraction and Synthesis
Data extraction was conducted by four independent researchers (C.C., A.M., R.P., R.P.)
from the end of January to February 2021. A dedicated data extraction form on Excel was
used to retrieve the following information for each eligible study:
1. Study identification (first author, title, journal, publication year);
2. Study characteristics (period, country, design);
3. Sample characteristics (stage of breast cancer, sample age, sample ethnicity);
4. Personalized Medicine and Patient centered aspects;
5. Barriers and/or success factors.
2.5. Quality Assessment
Three researchers (A.M., R.P., R.P.) independently conducted the methodological
quality assessment, based on the different study designs. Disagreements were resolved by
discussion with a fourth researcher (C.C.). The standardised critical appraisal tool (1) Scale
for the Assessment of Narrative Review Article SANRA [18] was used to assess narrative
reviews; (2) Critical Appraisal Skills Programme, CASP [19] for qualitative research; (3) JBI
Critical Appraisal Checklist for cohort studies [20]; (4) JBI Critical Appraisal Checklist for
text and opinion [21]; (5) The Newcastle-Ottawa Scale NOS for cross-sectional studies [22];
(6) JBI Critical Appraisal Checklist for systematic review and research syntheses [23]. To
summarise the overall evidence quality, we decided to cluster the records retrieved into
three categories, based on the number of quality criteria met: group 1, studies satisfied at
least 75% of the quality criteria; group 2, studies encountering between 55% and 74% of the
quality criteria; and group 3, studies met less than 55% of the quality criteria.
3. Results
A total of 1885 records were collected from all the databases searched. After removing
duplicates, the remaining 1806 articles were screened by title and abstract. The full texts
of the 83 retained papers were screened. Of these, 25 met the eligibility criteria and were
included in the systematic review and in the qualitative analysis.
The process of study screening and selection is reported in Figure 1.
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criteria, while the majority—11 [26,31,33,35,37–39,42–45] out of 25 articles (44%)—were 
allocated in group 2, meeting between 55% and 74% of the quality criteria. Lastly, 8 [28–
30,32,36,46–48] out of 25 studies (32%) were inserted in group 3, satisfying less than 55% 
of the quality criteria. 
Table 1. Summary results of quality assessment. 
Study Overall % Quality 
Biganzoli et al. 2017 [27] 83% Group 1 
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Komatsu et al. 2014 (39] 70% Group 2 
McGowan et al. 2016 [33] 60% Group 2 
Figure 1. PRISMA Flowchart of the literature review and selection process for breast cancer manage-
ment in terms of patient-centered care and personalized medicine a proaches.
3.1. Results of Quality Assessment
The majority of the included articles were narrative reviews [24–32] (36%) and qualitative
researches [33–39] (28%). As reported in Table 1, six [24,25,27,34,40,41] out of 25 articles (24%)
were classified in group 1, since they satisfied at least 75% of the quality criteria, while the
majority—11 [26,31,33,35,37–39,42–45] out of 25 articles (44%)—were allocated in group 2,
meeting between 55% and 74% of the quality criteria. Lastly, 8 [28–30,32,36,46–48] out of
25 studies (32%) were inserted in group 3, satisfying less than 55% of the quality criteria.
Table 1. Summary results of quality assessment.
Study Overall % Quality
Biganzoli et al. 2017 [27] 83% Group 1
Fountzilas et al. 2018 [25] 83% Group 1
Rosa 2015 [24] 83% Group 1
Jacobs et al. 2017 [40] 90% Group 1
Weldon et al. 2012 [34] 90% roup 1
Zardavas et al. 2013 [41] 83% roup 1
Cowppli-Bony et al. 2019 [42] 60% Group 2
Powis et al. 2017 [44] 60% Group 2
Wallerstedt et al. 2020 [45] 55% Group 2
Saini et al. 2019 [31] 67% roup 2
Schnapper et al. 2018 [37] 70% roup 2
Komatsu et al. 2014 [39] 70% Group 2
McGowan et al. 2016 [33] 60% Group 2
Wright et al. 2019 [35] 60% Group 2
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Table 1. Cont.
Study Overall % Quality
Kurian et al. 2017 [38] 60% Group 2
Kurian et al. 2015 [43] 67% Group 2
Trivedi et al. 2019 [26] 58% Group 2
Tischler et al. 2019 [29] 42% Group 3
Girotra et al. 2016 [30] 42% Group 3
Lyman et al. 2013 [28] 33% Group 3
Laronga et al. 2012 [32] 50% Group 3
Roberts et al. 2016 [36] 30% Group 3
van Hoeve et al. 2014 [48] 27% Group 3
Al-Naqqash 2020 [46] 45% Group 3
Perez 2011 [47] 33% Group 3
3.2. Outcome Categories
Below, we report findings relative to the key dimensions of Patient Centered Care
and Personalized Medicine, alongside relative key success factors and barriers as shown
in Table 2.
3.2.1. Patient-Centered Care Key Dimensions
The patient-centered care category included five [27,36,37,42,44] out of twenty-five
articles (20%). Findings relative to the key dimensions were:
• Communication: the description and analysis of communicative skills of clinicians [36]
(20%);
• Audit and feedback: the measurement of quality indicators and compliance with
the standards proposed by the European Society on Breast Cancer Specialists (EU-
SOMA) [27,42] (40%);
• Informative systems: their utility and effectiveness for management of cancer-related
data [37] (20%);
• Evidence-based application (guidelines, critical pathway, and procedures): the im-
provement of patients outcome required necessarily the adherence to the guide-
lines [42,44] (40%).
3.2.2. Personalized Medicine Key Dimensions
Eleven [24,28,30,32–35,41,43,45,46] out of twenty-five articles (44%) provided infor-
mation on personalized medicine for the treatment of breast cancer. Results about key
dimensions were:
• Molecular board (compositions and conditions for efficacy): the role, responsibilities and
tasks of all members, in particular pathologists and surgeons [24,28,32,33,35] (45%);
• Evidence-based genetic testing: the benefits and clinical validity of -omics technologies,
focusing on BRCA and Oncotype DX [24,30,32,34,35,41,43,45,46] (82%);
• Shared-clinical decision-making: a positive impact on the selection of targeted ther-
apy and improvements in chemotherapy, endocrine, and chemo-endocrine therapy
decisions [24,30,32,34,35,41,43,45,46] (82%).
Only three [24,32,35] out of eleven articles (27%) provided information on all three
dimensions, indicating that the combination of these would be necessary and essential to
ensure a more accurate and efficacy targeted treatment.
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Table 2. Summary of 25 studies on Breast Cancer management, evaluated in terms of Patient-Centered and Personalized Medicine approaches, assessing success factors and/or barriers.
Articles are listed in study design order.
Study Country Study Design Sample(Ethnicity/Age) Type of BC PM or/and PC Dimensions Involved Barriers Success Factors
Van Hoeve et al.
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3.2.3. Key Dimensions for Applying Personalized Medicine and Patient-Centered Care
Nine [25,26,29,31,38–40,47,48] out of twenty-five articles (36%) reported information
on both categories (PM and PC).
In particular, two [40,47] out of nine articles (22%) referred to the molecular board;
eight [25,26,29,31,38,39,47,48] (89%) referred to evidence-based genetic testing.
Information on shared-clinical decision-making was reported by six [26,29,31,38,47,48]
(66%): in particular, only one [31] described and analyzed several web supports to include
the patient in the decision-making process.
Four [29,38–40] (44%) referred to communication, focusing on a greater sharing of
information during genetic counselling.
One [48] (11%) referred to audit/feedback and two [26,39] (22%) to informative sys-
tems. Both agreed on the introduction of scientific tools, such as electronic medical records
(EMR), to combine clinical and genomic data.
Evidence-based application was described by only one study [48] (11%), with the
implementation of an integrated oncology clinical pathway model (IOCP).
Seven [25,26,29,31,39,40,47] (78%) referred to a multidisciplinary approach: most of
them agreed on the need for education and training programs about genetic testing for all
members of the multidisciplinary team.
3.3. Success Factors and Barriers in the Management of Breast Cancer Pathway
3.3.1. Success Factors
Analysis of the included articles revealed the following key success factors of the
enactment of personalized treatment and patient-centered care models in BC clinical prac-
tice, which can be summarized as follows: multiprofessional/multispecialist collaboration;
education and training on genetic testing; utilization of personalized medicine prevention
techniques; clear communication between clinicians and patients; data derived benchmark-
ing for quality improvement.
More specifically, appropriately training and assembling multi-professional and
multi-specialist teams is described as an organizational strength for the treatment of
BC [26,28,31–33,47]. In breast oncology practice, in fact, the team must necessarily include
qualified specialists to bridge the gap between clinical knowledge and genetic potential,
especially able to collect and evaluate genomic profiling data [31,33]. The importance of
refining clinicians’ training on genetic testing and communication strategies is also linked
to clinician-to-patient communication [36,38]: a communicative approach focused on pa-
tients and their background consent a better involvement of them in the decision-making
process [43]. In addition, measuring and benchmarking the performance of clinical path-
ways through quality indicators allow us to identify, on one side, weak areas that require
improvement and, on the other, those which adhered to clinical guidelines [42,44,48].
Lastly, another key success factor is found in the appropriateness of the genetic test
selection process, which must take into account clinical utility and validity, analytical
validity, as well as ethical, legal, and social implications [25].
3.3.2. Barriers
Our records allowed us to identify some general barriers that should be improved and
overcome in the future, such as the lack of a universal language among health professionals,
the uncertain composition of multidisciplinary teams and delays in the adoption of new
technologies in clinical practice.
The need for proper training and education for geneticists and clinicians [24,25,39] is not
supported by the adoption of a universal genomics vocabulary [41]. Additionally, the unclear
definition of the scope of the genetic counseling—or an insufficiently involved geneticist—
represents a barrier to proper and adequate communication with the patient [33,38]. From
here, the need to define the role of genetic counseling through internal protocols, both
before and after the execution of the tests, also serves as a barrier [40].
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Moreover, there seems to be lack of clarity on the allocation of tasks and responsibil-
ities among all members of the multidisciplinary team. Especially between oncologists
and geneticists, the administration, interpretation and use of genetic tests and -omics
technologies are fragmented [35], further confirming the importance of introducing new
professional profiles trained and responsible for data collection and analysis, such as data
manager [37].
The delay in the adoption of -omic technologies in clinical practice is associated to the
lack of clarity in their appropriate timing and use [39,41,44]. Furthermore, the insufficient
use of genetic testing is linked to the absence of public reimbursement schemes which
disincentivizes their utilization [34,46].
4. Discussion
Authors should discuss the results and how they can be interpreted from the perspec-
tive of previous studies and of the working hypotheses. The findings and their implications
should be discussed in the broadest context possible. Future research directions may also
be highlighted.
We systematically reported on the state-of-the-art of available literature investigating
the enactment of personalized treatment and patient-centered care models in BC clinical
practice. We also aimed at highlighting the key success factors of such a shift, alongside
relative barriers to implementation. The main success factors found in our included articles
are the clear definition of roles and responsibilities within a multi-professional collaboration,
backed by appropriate training and education programs. Last but not least, there is the
need for an adequate communication strategy which includes the adoption of a universal
genomic language and the active involvement of the patient in the decision-making process.
Overall, it appears that -omics technology cannot rely on a solid organizational structure,
neither at the micro level of single facilities or at the macro level of the health system.
Compared to El-Alti et al. 2019 [49], which questions whether the relationship between
personalized medicine and patient-centered care is a complementary or mutually exclusive
one, our study takes a step further and answers the question by supporting the thesis by
which these models are indeed synergically complementary.
In fact, PM alone is not sufficient to select the best treatment choice as it focuses mainly
on somatic, biological and genetic features of the patient. It is here that the role played
by Patient Centered Care ensures the active engagement of the patient by bringing his
personal needs and preferences into the decision-making process. Nardini et al. 2021 [50]
describe a new healthcare configuration that includes personalized, predictive, preventive,
participatory and person-centered care approaches, to be applied to all areas of medicine.
Agreeing with such findings, this review recognizes how both models together are needed
to ensure a positive and effective change in the path of patient care and attempts to tailor
such a transition to the context of breast cancer care.
With the next step being the delivery of personalized care, it becomes central to find
solutions to the array of organizational challenges that come with it to allow, on one side,
the high degree of specialization, scientific-technical advances and multidisciplinary and
multiprofessional coordination, and, on the other, patient participation and the ability to
respond to multiple care needs [51].
Internationally, clinical pathways have been recognized as a suitable tool to drive care
towards patient-centeredness, and result from a translation of Evidence Based Medicine
(EBM) principles into localized contexts (Figure 2), as a strategy to reduce unnecessary
clinical variability, costs, fragmentation of care improving outcomes and quality of care [52].
However, it has been argued that committing to one or a few best recommendations and
standards may slow down the pace of change in the landscape of oncological care and
prevent providers and professionals from being able to deliver individualized treatments
that synergize with patient preferences [53].
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Figure 3. The personalized pathway on breast cancer.
Structuring the pathway on specific moments of shared decision making—to be
applied not only between patients and healthcare professionals, but also between healthcare
professionals themselves; our model blends personalized medicine and patient centered
care determinants, such as each patients’ genetic features (i.e., the genomic profile), impacts
on the patient’s health status (including patient safety and treatment adverse effects) and
patient reported measures (PROMs and PREMs).
Additionally, however, following the direction taken by Value-Based Healthcare and,
in particular Bodenheimer’s Quadruple-Aim framework [59], the next generation of care
pathway’s framework must include also other three dimensions: at an organizational micro
level, the framework considers care-team sharing, being a determinant of team wellness;
at a macro-organizational level, the principles of green oncology, waste containment and
impacts on overall budget and accountability, to evaluate the broadest i pact possible of
the dynamic pathway.
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5. Limitations
There are some limitations in this systematic review that should be taken into account
when interpreting the results. First of all, broadly speaking, evidence in the current
literature of primary studies clearly defining the combined use of personalized medicine
and patient-centered care approaches were quite scarce. Secondly, heterogeneity in study
designs, in outcome definition and in staging systems adopted (often not at all present
in the included studies) prevented us from conducting a meta-analysis and issuing more
conclusive results. Furthermore, according to the adopted quality assessment tools, most
of the included studies were of moderate–poor quality.
6. Conclusions
In the last few years, patient-centered care has been found to be one of the key
elements for improving the quality of breast cancer management. Clinical-care-pathways,
especially oncological ones, have certainly contributed to the transparency of the decision-
making process. The pressure that personalized medicine is placing in the field of oncology,
however, highlights the need to structure organizational models that combine PC care
models and PM together. The sustainability of the model proposed in this work would
largely benefit from further developments and confirmations through additional research,
as well as in ulterior organizational contexts.
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